Human behavioral pharmacology, past, present, and future: Symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society

Behavioural Pharmacology

Volumn 21, Issue 4, 2010, Pages 251-277

  Comer, Sandra D ^a   Bickel, Warren K ^b   Yi, Richard ^b   De Wit, Harriet ^d   Higgins, Stephen T ^e   Wenger, Galen R ^c   Johanson, Chris Ellyn ^f   Kreek, Mary Jeanne ^g  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Department of Psychiatry ^*  (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF VERMONT   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g ROCKEFELLER UNIVERSITY   (United States)

Author keywords

50th Annual Meeting; Behavioral Pharmacology Society; drugs; human behavioral pharmacology; self administration; symposium

Indexed keywords

BUPRENORPHINE; METHADONE; NICOTINE; OPIATE;

ADDICTION; BEHAVIORAL MEDICINE; CIGARETTE SMOKING; CONFERENCE PAPER; DRUG ABUSE; DRUG ADMINISTRATION; ECONOMIC ASPECT; EVOLUTION; GENOTYPE; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; NEUROSCIENCE; NONHUMAN; PERSONALITY; PHARMACOLOGY; PHENOTYPE; SEX DIFFERENCE; SMOKING CESSATION; SUBSTANCE ABUSE; SYMPOSIUM; BEHAVIOR; DRUG EFFECTS; DRUG SELF ADMINISTRATION; HISTORY; INDIVIDUALITY; PSYCHOLOGY; REINFORCEMENT; SUBSTANCE-RELATED DISORDERS; TRENDS;

BEHAVIOR; HISTORY, 20TH CENTURY; HUMANS; INDIVIDUALITY; PHARMACOLOGY; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 77955168896     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833bb9f8     Document Type: Conference Paper

References (241)

1. Ainslie G (1974). Impulse control in pigeons. J Exp Anal Behav 21:485-489.
2. Ainslie G (1975). Specious reward: a behavioral theory of impulsiveness and impulse control. Psychol Bull 82:463.
3. Alessi SM, Petry NM (2003). Pathological gambling severity is associated with impulsivity in a delay discounting procedure. Behav Proc 64:345-354.
4. Alsene KM, Deckert J, Sand P, de Wit H (2003). Increased anxiety after acute caffeine associated with adenosine A2A receptor polymorphism. Neuropsychopharmacology 28:1694-1702.
5. Altman JL, Meyer RE, Mirin SM, McNamee HB (1976). Opiate antagonists and the modification of heroin self-administration behavior in man: an experimental study. Int J Addict 1:485-499.
6. Arnold JM, Roberts DCS (1997). A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 57:441-447.
7. Azatian A, Papiasvilli A, Joseph H (1994). A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR. J Addict Dis 13:35-52.
8. Baker F, Johnson MW, Bickel WK (2003). Delay discounting differs between current and never-smokers across commodities, sign, and magnitudes. J Abn Psychol 112:382-392.
9. Baler RD, Volkow ND (2006). Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med 12:559.
10. Barkley RA (1997). Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 121:65-94.
11. Bart G, LaForge KS, Borg L, Lilly C, Ho A, Kreek MJ (2006). Altered levels ofbasal cortisol in healthy subjects with a 118G allele in exon 1 of the mu opioid receptor gene. Neuropsychopharmacology 31:2313-2317.
12. Bechara A (2005). Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective. Nat Neurosc 8:1458-1463.
13. Becker JB, Cha J (1989). Estrous cycle-dependent variation in amphetamine-induced behaviors and striatal dopamine release assessed with microdialysis. Behav Brain Res 35:117-125.
14. Becker JB, Robinson TE, Lorenz KA (1982). Sex differences and estrous cycle variations in amphetamine-elicited rotational behavior. Eur J Pharmacol 80:65-72.
15. Bickel WK, Marsch LA (2001). Toward a behavioral economics understanding of drug dependence: delay discounting processes. Addiction 96:73-86.
16. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988). A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 43:72-78.
17. Bickel WK, Amass L, Crean JP, Badger GJ (1999a). Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology 146:111-118.
18. Bickel WK, Odum AL, Madden GJ (1999b). Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers. Psychopharmacology 146:447-454.
19. Bickel WK, Marsch LA, Carroll ME (2000). Deconstructing relative reinforcing efficacy and situating the measure of pharmacological reinforcement with behavioral economics: a theoretical proposal. Psychopharmacology 153:44-56.
20. Bickel WK, Miller ML, Yi R, Kowal BP, Lindquist DM, Pitcock JA (2007). Behavioral and neuroeconomics of drug addiction: competing neural systems and temporal discounting processes. Drug Alcohol Dependence 90S:S85-S91.
21. Bigelow G, Griffiths R, Liebson I (1976). Experimental human drug self-administration: methodology and application to the study of sedative abuse. Pharmacol Rev 27:523-531.
22. Bigelow GE, Griffiths RR, Liebsen IA (1977). Pharmacological influences upon human ethanol self-administration. Adv Exp Med Bio 85B:523-538.
23. Bjork JM, Hommer DW, Grant SJ, Danube C (2004). Impulsivity in abstinent alcohol-dependent patients: relation to control subjects and type-1/type 2-like traits. Alcohol 34:133-150.
24. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, et al. (1998). Singlenucleotide polymorphism in the human mu-opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95:9608-9613.
25. Borghans L, Golsteyn BHH (2006). Time discounting and the body mass index: evidence from the Netherlands. Econ Hum Biol 4:39.
26. Bozarth MA, Wise RA (1985). Toxicity associated with long-term intravenous heroin and cocaine self-administration in the rat. JAMA 254:81-83.
27. Callahan EJ, Rawson RA, McCleave B, Arias R, Glazer M, Liberman RP (1980). The treatment of heroin addiction: naltrexone alone and with behavior therapy. Int J Addict 15:795-807.
28. Catania AC (1963). Concurrent performances: a baseline for the study of reinforcement magnitude. J Exp Anal Behav 6:299-300.
29. Catania AC (1991). Glossary. In: Iversen IH, Lattal KA, editors. Experimental analysis of behavior. St Louis, Missouri, USA: Elsevier Science Publishers BV; pp. G32-G33.
30. Chong RY, Oswald L, Yang X, Uhart M, Lin PI, Wand GS (2006). The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 31:204-211.
31. Chung SH, Herrnstein RJ (1967). Choice and delay of reinforcement. J Exp Anal Behav 10:67-74.
32. Cloninger C (1987). Neurogenetic adaptive mechanisms in alcoholism. Science 236:410-416.
33. Coffey SF, Gudleski GD, Saladin ME, Brady KT (2003). Impulsivity and rapid discounting of delayed hypothetical rewards in cocaine-dependent individuals. Exp Clin Psychopharmacol 11:18-25.
34. Colpaert FC, De Witte PH, Maroli AN, Awouters F, Niemegeers CJE, Janssen PAJ (1980). Self-administration of the analgesic suprofen in arthritic rats: evidence of mycobacterium butyricum-induced arthritis as an experimental model of chronic pain. Life Sci 27:921-928.
35. Colpaert FC, Meert TH, De Witte PH, Schmitt P (1982). Further evidence validating adjuvant arthritis as an experimental model of chronic pain in the rat. Life Sci 31:67-75.
36. Colpaert FC, Tarayre JP, Alliaga M, Bruins Slot LA, Attal N, Koek W (2001). Opiate self-administration as a measure of chronic nociceptive pain in arthritic rats. Pain 91:33-45.
37. Comer SD, Collins ED, Fischman MW (2001). Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology 154:28-37.
38. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW (2002). Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 159:351-360.
39. Comer SD, Walker EA, Collins ED (2005). Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 181:664-675.
40. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63:210-218.
41. Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, Walsh SL (2008). The role of human drug self-administration procedures in the development of drugs. Drug Alcohol Depend 96:1-15.
42. Daw ND, Niv Y, Dayan P (2005). Uncertainty-based competition between prefrontal and dorsolateral striatal systems for behavioral control/Uncertainty- based competition between prefrontal and dorsolateral striatal systems for behavioral control. Nat Neurosci 8:1704.
43. De Wit H (2005.) Relationships between personality and acute subjective responses to stimulant drugs. In: Earleywine M, editor. Mind-altering drugs: the science of subjective experience. New York: Oxford University Press Inc.; pp. 258-274.
44. De Wit H, Chutuape MA (1993). Increased ethanol choice in social drinkers following ethanol preload. Behav Pharmacol 4:29-36.
45. De Wit H, Uhlenhuth EH, Johanson CE (1986). Individual differences in the behavioral and subjective effects of amphetamine and diazepam. Drug Alcohol Depend 16:341-360.
46. De Wit H, Uhlenhuth EH, Pierri J, Johanson CE (1987). Individual differences in behavioral and subjective responses to alcohol. Alcoholism: Clin Exp Res 11:52-59.
47. Deneau GE, Yanagita T, Seevers M (1969). Self-administration of psychoactive substances by the monkey-a measure of psychological dependence. Psychopharmacology (Berl) 16:30-48.
48. Depue RA, Collins PF (1999). Neurobiology of the structure of personality: dopamine, facilitation of incentive motivation, and extraversion. Behav Brain Sci 22:491-517.
49. Dixon MR, Marley J, Jacobs EA (2003). Delay discounting by pathological gamblers. J App Behav Anal 36:449-458.
50. Dole VP, Nyswander ME (1965). A medical treatment for diacetylmorphine (heroin) addiction. JAMA 193:646-650.
51. Dole VP, Nyswander ME, Kreek MJ (1966a). Narcotic blockade: a medical technique for stopping heroin use by addicts. Trans Assoc Am Phys 79:122-136.
52. Dole VP, Nyswander ME, Kreek MJ (1966b). Narcotic blockade. Arch Intern Med 118:304-309.
53. Dom G, D'haene PD, Hulstijn W, Sabbe B (2006). Impulsivity in abstinent early-and late-onset alcoholics: differences in self-report measures and a delay discounting task. Addiction 101:50-59.
54. Donlin WD, Knealing TW, Silverman K (2008.) Employment-based reinforcement in the treatment of drug addiction. In: Higgins ST, Silverman K, Heil SH, editors. Contingency management in substance abuse treatment. New York: Guilford Press; pp. 314-333.
55. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL (2005). Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100:1496-1509.
56. Drebing CE, VanOrmer EA, Krebs C, Rosenheck R, Rounsaville B, Herz L, et al. (2005). The impact of enhanced incentives on vocational rehabilitation outcomes for dually-diagnosed veterans. J Appl Behav Anal 38:359-372.
57. Elkins IJ, King SM, McGue M, Iacono WG (2006). Personality traits and the development of nicotine, alcohol, and illicit drug disorders: prospective links from adolescence to young adulthood. J Abn Psychol 115:26-39.
58. Evans SM, Haney M, Foltin RW (2002). The effects of smoked cocaine during the follicular and luteal phases of the menstrual cycle in women. Psychopharma-cology 159:397-406.
59. Everitt BJ, Robbins TW (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8:1481-1489.
60. Fein G, Di Sclafani V, Meyerhoff DJ (2002). Prefrontal cortical volume reduction associated with frontal cortex function deficit in 6-week abstinent crack-cocaine dependent men. Drug Alcohol Depend 68:87.
61. Field M, Santarcangelo M, Sumnall H, Goudie A, Cole J (2006). Delay discounting and the behavioral economics of cigaette purchases in smokers: the effects of nicotine deprivation. Psychopharmacology 186:255-263.
62. Field M, Christiansen P, Cole J, Goudie A (2007). Delay discounting and the alcohol Stroop in heavy drinking adolescents. Addiction 102:579-586.
63. Findley JP (1962). An experimental outline for building and exploring multi-operant behavior repertoires. J Exp Anal Behav 5 (Suppl):113-166.
64. Findley JP, Robinson WW, Peregrino L (1972). Addiction to secobarbital and chlordiazepoxide in the rhesus monkey by means of a self-infusion preference procedure. Psychopharmacologia 26:93-114.
65. Fischman MW, Schuster CR (1982). Cocaine self-administration in humans. Fed Proc 41:241-246.
66. Fischman MW, Foltin RW (1991). Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Brit J Addiction 86:1563-1570.
67. Fischman MW, Foltin RW, Nestadt G, Pearlson GD (1990). Effects of desipramine maintenance on cocaine self-administration by humans. J Pharmacol Exp Ther 253:760-770.
68. Foltin RW, Fischman MW (1991). Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 28:3-48.
69. Franklin TR, Acton PD, Maldjian JA, Gray JD, Croft JR, Dackis CA, et al. (2002). Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biol Psychiatry 51:134-142.
70. Giordano LA, Bickel WK, Shahan TA, Badger GJ (2001). Behavioral economics of human drug self-administration: progressive ratio vs. random sequences of response requirements. Behav Pharmacol 12:343-347.
71. Giordano LA, Bickel WK, Loewenstein G, Jacobs EA, Marsch L, Badger GJ (2002). Mild opioid deprivation increases the degree that opioid-dependent outpatients discounting delayed heroin and money. Psychopharmacology 163:174-1112
72. Goldberg SR, Woods JH, Schuster CR (1969). Morphine: conditioned increases in self-administration in rhesus monkeys. Science 166:1306-1307.
73. Goldman D, Oroszi G, Ducci F (2005). The genetics of addictions: uncovering the genes. Nat Rev: Genetics 6:521-532.
74. Green L, Hale S (1984). Practical implications of the matching law. J Appl Behav Anal 17:367-380.
75. Greenwald MK, Johanson CE, Schuster CR (1999). Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. Drug Alc Depend 56:191-203.
76. Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, et al. (2003). Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000-2009.
77. Griffiths RR, Bigelow GE, Liebson IA (1976). Human sedative self-administration: effects of interingestion interval and dose. J Pharmacol Exp Ther 197:488-494.
78. Griffiths RR, Bigelow GE, Henningfield JE (1980a). Similarities in animal and human drug-taking behavior. In: Mello NK, editor. Advances in substance abuse. Greenwich, Connecticut: JAI Press Inc.; pp. 1-90.
79. Griffiths RR, Bigelow GE, Liebson IA, Kaliszak JE (1980b). Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam, and placebo. J Pharmacol Exp Ther 215:649-661.
80. Griffiths RR, Henningfield JE, Bigelow GE (1982). Human cigarette smoking: manipulation of number of puffs per bout, interbout interval, and nicotine dose. J Pharmacol Exp Ther 220:256-265.
81. Griffiths RR, Bigelow GE, Liebson IA (1986). Human coffee drinking: rein-forcing and physical dependence producing effects of caffeine. J Pharmacol Exp Ther 239:416-425.
82. Griffiths RR, Troisi JR, Silverman K, Mumford GK (1993). Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 4:3-13.
83. Gross J, Johnson J, Sigler L, Stitzer ML (1995). Dose effect of nicotine gum. Addict Behav 20:371-381.
84. Han SC, Evans SM (2005). Sex and drugs. In: Earleywine M, editors. Mind-altering drugs: the science of subjective experience. New York: Oxford University Press Inc; pp. 183-216.
85. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, et al. (2006). Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 79:456-467.
86. Heil SH, Johnson MW, Higgins ST, Bickel WK (2006). Delay discounting in currently using and currently abstinent cocaine-dependent outpatients and non-drug-using matched controls. Addict Behav 31:1290-1294.
87. Henningfield JE (1995). Nicotine medications for smoking cessation. N Engl J Med 333:1196-1203.
88. Henningfield JE, Cohen C, Heishman SJ (1991). Drug self-administration methods in abuse liability evaluation. Brit J Addict 86:1571-1577.
89. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR (2003). Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet 118:60-65.
90. Herrnstein RJ (1961). Relative and absolute strength of response as a function of frequency of reinforcement. J Exp Anal Behav 4:267-272.
91. Heyman GM, Gibb SP (2006). Delay discounting in college cigarette chippers. Behav Pharmacol 17:669-679.
92. Higgins ST, Delaney DD, Budney AJ, Bickel WK, Hughes JR, Foerg F, et al. (1991). A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry 148:1218-1224.
93. Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ (1994). Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 51:568-576.
94. Higgins ST, Wong CJ, Badger GJ, Ogden DE, Dantona RL (2000). Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. J Consult Clin Psychol 68:64-72.
95. Higgins ST, Heil SH, Solomon LJ, Bernstein IM, Lissier JP, Abel RL, et al. (2004). A pilot study on voucher-based incentives to promote abstinence from cigarette smoking during pregnancy and postpartum. Nicotine Tob Res 6:1015-1020.
96. Hodos W (1961). Progressive ratio as a measure of reward strength. Science 134:943-944.
97. Hoffman WF, Moore M, Templin R, McFarland B, Hitzemann RJ, Mitchel SH (2006). Neuropsychological function and delay discounting in methamphe-tamine-dependent individuals. Psychopharmacology 188:162-170.
98. Holdstock L, de Wit H (1999). Individual differences in response to ethanol and triazolam. Behav Pharmacol 10:283-295.
99. Hughes JR (1999). Smoking cessation. N Engl J Med 341:610-611.
100. Hughes JR, Miller SA (1984). Nicotine gum to help stop smoking. JAMA 252:2855-2858.
101. Hughes JR, Hatsukami D (1986). Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289-294.
102. Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A (1984). Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 83:82-87.
103. Hughes JR, Goldstein MG, Hurt RD, Shiffman S (1999). Recent advances in the pharmacotherapy of smoking. JAMA 281:72-76.
104. Jaffe JH, Schuster CR, Smith BB, Blachley PH (1970). Comparison of acetylmethadol and methadone in the treatment of long-term heroin users. A pilot study. JAMA 211:1834-1836.
105. Jaffe JH, Senay EC, Schuster CR, Renault PR, Smith B, DiMenza S (1972). Methadyl acetate vs. methadone. A double-blind study in heroin users. JAMA 222:437-442.
106. Jarvik ME, Henningfield JE (1988). Pharmacological treatment of tobacco dependence. Pharmacol Biochem Behav 30:279-294.
107. Jasinski DR (1991). History of abuse liability testing in humans. British J Addict 86:1559-1562.
108. Jentsch JD, Taylor JR (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology 146:373-390.
109. Johanson CE, Schuster CR (1975). A choice procedure for drug reinforcers: cocaine and methylphenidate in the rhesus monkey. J Pharmacol Exp Ther 193:676-688.
110. Johanson CE, Balster RL (1978). A summary of the results of a drug self-administration study using substitution procedures in rhesus monkeys. Bull Narc 30:43-54.
111. Johanson CE, Uhlenhuth EH (1980). Drug preference and mood in humans: d-amphetamine. Psychopharmacology 71:275-279.
112. Johanson C, Uhlenhuth EH (1980a). Drug preference and mood in humans: diazepam. Psychopharmacology 71:269-273.
113. Johanson CE, Uhlenhuth EH (1980b). Drug preference and mood in humans: d-amphetamine. Psychopharmacology 71:275-279.
114. Johanson CE, Schuster CR (1981). Animal models of drug self-administration. Adv Subst Abuse 2:219-297.
115. Johanson CE, Balster RL, Bonese K (1976). Self-administration of psychomotor stimulant drugs: the effects of unlimited access. Pharmacol Biochem Behav 4:45-51.
116. Johnson RE, Jaffe JH, Fudala PJ (1992). A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267:2750-2755.
117. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE (1995). A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 40:17-25.
118. Johanson CE, Schuster CR, Hatsukami D, Vocci F, editors (2003). Abuse liability assessment of CNS drugs. Drug Alcohol Depend 70:S1-S114.
119. Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, et al. (2005). Buprenorphine vs. methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 79:1-10.
120. Justice AJH, de Wit H (1999). Acute effects of d-amphetamine during the follicular and luteal phases of the menstrual cycle in women. Psychopharma-cology 145:67-75.
121. Justice AJH, de Wit H (2000). Acute effects of amphetamine during the early and late follicular phase of the menstrual cycle in women. Pharmacol Biochem Behav 66:509-515.
122. Kantak KM, Goodrich GM, Uribe V (2007). Influence of sex, estrous cycle, and drug-onset age on cocaine self-administration in rats (Rattus norvegicus). Exp Clin Pyschopharmacol 15:37-47.
123. Katz JL (1990). Models of relative reinforcing efficacy of drugs and their predictive utility. Behav Pharmacol 1:283-301.
124. Kelly TH, Robbins G, Martin CA, Fillmore MT, Lane SD, Harrington NG, et al. (2006). Individual differences in drug abuse vulnerability: d-amphetamine and sensation-seeking status. Psychopharmacology (Berl) 189:17-25.
125. Kirby KN, Petry NM (2004). Heroin and cocaine abusers have higher discount rates for delayed rewards than alcoholics or non-drug-using controls. Addiction 99:461-471.
126. Kirby KN, Petry NM, Bickel WK (1999). Heroin addicts have higher discounting rates for delayed rewards than non-drug using controls. J Exp Psychol: Gen 128:78-87.
127. Koob G, Kreek MJ (2007). Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 164:1149-1159.
128. Kosten TR, Kleber HD (1984). Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse 10:249-266.
129. Kozlowski LT, Jarvik ME, Gritz ER (1975). Nicotine regulation and cigarette smoking. Clin Pharmacol Ther 17:93-97.
130. Kreek MJ (1973). Plasma and urine levels of methadone. NY State J Med 73:2773-2777.
131. Kreek MJ (2000). Methadone-related opioid agonist pharmacotherapy for heroin addiction: history, recent molecular and neurochemical research and the future in mainstream medicine. Ann NY Acad Sci 909:186-216.
132. Kreek MJ (2006). Endorphins, gene polymorphisms, stress responsivity, and special addictions: selected topics. In: Madras B, Colvis CM, Pollock JD, et al. editors. Cell biology of addiction. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; pp. 63-92.
133. Kreek MJ (2008). Role of a functional human gene polymorphism in stress responsivity and addictions. Clin Pharmacol Ther 83:615-618.
134. Kreek MJ, LaForge KS (2007). Stress responsivity, addiction, and a functional variant of the human mu opioid receptor gene. Molec Interv 7:74-78.
135. Kreek MJ, LaForge KS, Butelman E (2002). Pharmacotherapy of addictions. Nat Rev Drug Discov 1:710-726.
136. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS (2005). Genetic influences on impulsivity, risk-taking, stress responsivity, and vulnerability to drug abuse and addiction. Nat Neurosci 8:1450-1457.
137. Krishnan-Sarin S, Duhig AM, McKee SA, McMahon TJ, Liss T, McFetridge A, et al. (2006). Contingency management for smoking cessation in adolescent smokers. Exp Clin Psychopharmacol 14:306-310.
138. Krishnan-Sarin S, Reynolds B, Duhig AM, Smith A, Liss T, McFetridge A, et al. (2007). Behavioral impulsivity predicts treatment outcome in a smoking cessation program for adolescent smokers. Drug Alcohol Depend 88:79-82.
139. 35S]GTPgS binding. Synapse 47:243-249.
140. LaForge KS, Yuferov V, Kreek MJ (2000). Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol 410:249-268.
141. Leventhal A, Waters A, Boyd S, Moolchan E, Lerman C, Pickworth W (2007). Gender differences in acute tobacco withdrawal: effects on subjective, cognitive, and physiological measures. Exp Clin Psychopharmacol 15:21-36.
142. Liebson RA, Tommasello A, Bigelow GE (1978). A behavioral treatment of alcoholic methadone patients. Ann Intern Med 89:342-343.
143. Lile JA, Stoops W, Glaser PEA, Hays LR, Rush CR (2004). Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug Alcohol Depend 76:81-91.
144. Ling W, Wesson DR, Charuvastra C, Klett J (1996). A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 53:410-1407
145. Lott DC, Kim SJ, Cook EH, de Wit H (2005). Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsy-chopharmacology 30:602-609.
146. Lukas SE, Sholar M, Lundahl LH, Lamas X, Kouri E, Wines JD, et al. (1996). Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. Psychopharmacology (Berl) 125:346-354.
147. Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST (2006). A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 101:192-203.
148. Lynch WJ (2007). Sex differences in vulnerability to addiction. Exp Clin Psychopharmacology 14:34-41.
149. Lynch WJ, Roth ME, Carroll ME (2002). Biological basis of sex differences in drug abuse: preclinical and clinical studies. Pychopharmacology 164:121-137.
150. Madden GJ, Petry NM, Badger GJ, Bickel WK (1997). Impulsive and self-control choices in opioid-dependent patients and non-drug-using control participants: drug and monetary rewards. Exp Clin Psychopharmacol 5:256-262.
151. Mantsch JR, Schlussman SD, Ho A, Kreek MJ (2000). Effects of cocaine self-administration on plasma corticosterone and prolactin in rats. J Pharmacol Exp Ther 294:239-247.
152. Mantsch JR, Yuferov V, Mathieu-Kia AM, Ho A, Kreek MJ (2004). Effects of extended access to high vs. low cocaine doses on self-administration, cocaine-induced reinstatement and brain mRNA levels in rats. Psychophar-macology (Berl.) 175:26-36.
153. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al. (2005). Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry 62:1157-1164.
154. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, Broft A, et al. (2007). Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164:622-629.
155. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. (2003). Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Nat Acad Sci 100:6186-6191.
156. Mazur JE (1987). An adjusting procedure for studying delayed reinforcement. In: Commons ML, Mazur JE, Nevin JA, Rachlin H, editors. Quantitative analysis of behavior. Vol.5. Hillsdale, NJ: Erlbaum; pp. 55-73.
157. McCaul ME, Stitzer ML, Bigelow GE, Liebson IA (1984). Methadone detoxification: effects of methadone dose vs. time in treatment. NIDA Res Monograph 49:269-274.
158. McClure SM, Laibson DL, Loewenstein G, Cohen JD (2004). Separate neural systems value immediate and delayed monetary rewards. Science 306:503-507.
159. McClure SM, Ericson KM, Laibson DI, Loewenstein G, Cohen JD (2007). Time discounting for primary rewards. J Neurosci 27:5796-5804.
160. McDowell D, Nunes EV, Seracini AM, Rothenberg J, Vosburg SK, Ma GJ, et al. (2005). Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial. Drug Alc Depend 80:209-221.
161. Mello NK (1978). Behavioral pharmacology of narcotic antagonists. NIDA Res Monogr 19:126-141.
162. Mello NK, Mendelson JH (1965). Operant analysis of drinking patterns of chronic alcoholics. Nature (London) 206:43-46.
163. Mello NK, Mendelson JH (1980). Buprenorphine suppresses heroin use by heroin addicts. Science 207:657-659.
164. Mello NK, Mendelson JH, Kuehnle JC, Sellers MS (1981). Operant analysis of human heroin self-administration and the effects of naltrexone. J Pharmacol Exp Ther 216:45-54.
165. Mendelson JH, Mello NK (1966). Experimental analysis of drinking behavior of chronic alcoholics. Ann N Y Acad Sci 133:828-845.
166. Mendelson JH, Mello NK (1976). Behavioral and biochemical interrelations in alcoholism. Annu Rev Med 27:321-333.
167. Mendelson JH, Kuehnle JC, Greenberg I, Mello NK (1976). Operant acquisition of marihuana in man. J Pharmacol Exp Ther 198:42-53.
168. Mitchell SH (1999). Measures of impulsivity in cigarette smokers and nonsmokers. Psychopharmacol 146:455-464.
169. Mitchell JM, Fields HL, D'Esposito M, Boettiger CA (2005). Impulsive responding in alcoholics. Alcoholism: Clin Exp Res 29:2158-2169.
170. Montague PR, Berns GS (2002). Neural economics and the biological substrates of valuation. Neuron 36:264-284.
171. Monterosso JR, Ainslie G, Xu J, Cordova X, Domier CP, London ED (2007). Frontoparietal cortical activity of methamphetamine-dependent and comparison subjects performing a delay discounting task. Hum Brain Mapp 28:383-393.
172. Mumenthaler MS, Taylor JL, O'Hara R, Fisch HU, Yesavage JA (1999). Effects of menstrual cycle and female sex steroids on ethanol pharmacokinetics. Alcoholism: Clin Exp Res 23:250-255.
173. Myerson J, Green L, Warusawitharana M (2001). Area under the curve as a measure of discounting. J Exp Anal Behav 76:235-243.
174. Odum AL, Madden GJ, Badger GJ, Bickel WK (2000). Needle sharing in opioid-dependent outpatients: psychological processes underlying risk. Drug Alcohol Depend 60:259-266.
175. Ohmura Y, Takahashi T, Kitamura N (2005). Discounting delayed and probabilistic monetary gains and losses by smokers of cigarettes. Psychopharmacology 182:508-515.
176. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, et al. (2003). A functional polymorphism of the m-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsycho-pharmacology 28:1546-1552.
177. Peirce JM, Petry NM, Stitzer ML, Blaine J, Kellogg S, Satterfield F, et al. (2006). Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National drug abuse treatment clinical trials network study. Arch Gen Psychiatry 63:201-208.
178. Perkins KA, Donny E, Caggiula AR (1999). Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nic Tob Res 1:301-315.
179. Perkins KA, Fonte C, Meeker J, White W, Wilson A (2001a). The discriminative stimulus and reinforcing effects of nicotine in humans following nicotine pretreatment. Behav Pharmacol 12:35-44.
180. Perkins KA, Gerlach D, Vender J, Grobe J, Meeker J, Hutchison S (2001b). Sex differences in the subjective and reinforcing effects of visual and olfactory cigarette smoke stimuli. Nic Tob Res 3:141-150.
181. Petry NM (2001a). Pathological gamblers, with and without substance use disorders, discount delayed rewards at high rates. J Abn Psychol 110:482-487.
182. Petry NM (2001b). Delay discounting of money and alcohol in actively using alcoholics, currently abstinent alcoholics, and controls. Psychopharmacology 154:243-250.
183. Petry NM, Peirce JM, Stitzer ML, Blaine J, Roll JM, Cohen A, et al. (2005). Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trial network study. Arch Gen Psychiatry 62:1148-1156.
184. Pickens R (1979). A behavioral program for treatment of drug dependence. NIDA Res Monograph 25:44-54.
185. Pickens R, Harris WC (1968). Self-administration of d-amphetamine by rats. Psychopharmacologia 12:158-163.
186. Pickens R, Bigelow G, Griffiths RR (1973). An experimental approach to treating chronic alcoholism: a case study and one-year follow-up. Behav Res Ther 11:321-325.
187. Prendergast M, Podus D, Finney J, Greenwell L, Roll J (2006). Contingency management for treatment of substance use disorders: a meta-analysis. Addiction 101:1546-1560.
188. Rachlin H, Raineri A, Cross D (1991). Subjective probability and delay. J Exp Anal Behav 55:233-244.
189. Redish AD, Johnson A (2007). A computational model of craving and
190. Reif A, Lesch KP (2003). Toward a molecular architecture of personality. Behav Brain Res 139:1-20.
191. Reynolds B (2006). A review of delay-discounting research with humans: relations to drug use and gambling. Behav Pharmacol 17:651-667.
192. Reynolds B, Richards JB, Horn K, Karraker K (2004). Delay and probability discounting as related to cigarette smoking status in adults. Behav Proc 65:35-42.
193. Robbins TW, Murphy ER (2006). Behavioural pharmacology: 40 + years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol Sci 27:141.
194. Roehrs T, Pedrosi B, Rosenthal L, Zorick F, Roth T (1997). Hypnotic self-administration: forced-choice vs. single-choice. Psychopharmacology 133: 121-126.
195. Rose JE, Jarvik ME, Rose KD (1984). Transdermal administration of nicotine. Drug Alcohol Depend 13:209-213.
196. Rowlett JK (2000). A labor-supply analysis of cocaine self-administration under progressive-ratio schedules: antecedents, methodologies, and perspectives. Psychopharmacology 153:1-16.
197. SAMHSA (2006); Substance Abuse and Mental Health Services Administration 2005 National Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies.
198. Sanfey AG, Loewenstein G, McClure SM, Cohen JD (2006). Neuroeconomics: cross-currents in research on decision-making. Trends Cogn Sci 10:108.
199. Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, et al. (1995). Efficacy of a nicotine spray in smoking cessation: a placebo-controlled double-blind trial. Addiction 90:1671-1682.
200. Schuster CR, Smith BB, Jaffe JH (1971). Drug abuse in heroin users. An experimental study of self-administration of methadone, codeine, and pentazocine. Arch Gen Psychiatry 24:359-362.
201. Shahan TA, Bickel WK, Madden GJ, Badger GJ (1999). Comparing the reinforcing efficacy of nicotine containing and de-nicotinized cigarettes: a behavioral economic analysis. Psychopharmacology 147:210-216.
202. Sher KJ, Wood MD (2005). Subjective effects of alcohol II. In: Earleywine M, editor. Mind-altering drugs: the science of subjective experience. New York: Oxford University Press Inc.; pp. 135-153.
203. Sher KJ, Trull TJ, Bartholow B, Vieth A (1999). Personality and alcoholism: issues methods, and etiological processes. In: Blane H, Leonard K, editors. Psychological theories of drinking and alcoholism. 2nd ed. New York: Plenum; pp. 55-105.
204. Shiffman SM, Jarvik ME (1976). Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology 50:35-39.
205. Sigmon SC, Moody DE, Nuwayser ES, Bigelow GE (2006). An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 101:420-432.
206. Silverman K, Kirby KC, Griffiths RR (1994). Modulation of drug reinforcement by behavioral requirements following drug ingestion. Psychopharmacol 114:243-247.
207. Silverman K, Higgins ST, Brooner RK, Montoya ID, Cone EJ, Schuster CR, Preston KL (1996). Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry 53:409-415.
208. Silverman K, Wong CG, Umbricht-Schneiter A, Montoya ID, Schuster CR, Preston KL (1998). Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin Psychol 66:811-824.
209. Silverman K, Svikis D, Wong CJ, Hampton J, Stitzer ML, Bigelow GE (2002). A reinforcement-based therapeutic workplace for the treatment of drug abuse: three year abstinence outcomes. Exp Clin Psychopharmacol 10:228-240.
210. Skinner BF (1959). Animal research in the pharmacotherapy of mental disease. In: Cole JO, Gerard RW, editors. Psychopharmacology: problems in evalution. Washington, DC: National Academy of Sciences; pp. 224-235. (NAS-NRC Publication No. 583
211. Sobel B-FX, Sigmon SC, Griffiths RR (2004). Transdermal nicotine maintenance attenuates the subjective and reinforcing effects of intravenous nicotine, but not cocaine or caffeine, in cigarette-smoking stimulant abusers. Neuropsy-chopharmacology 29:991-1003.
212. Spragg SDS (1940). Morphine addiction in chimpanzees. Comp Psychol Monogr 15:1-132.
213. Stafford D, LeSage MG, Glowa JR (1998). Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharma-cology 139:169-184.
214. Stern KN, Chait LD, Johanson CE (1989). Reinforcing and subjective effects of oral tripelennamine in normal human volunteers. Behav Pharmacol 1:161-167.
215. Stitzer ML, Bigelow GE (1984). Contingent reinforcement for carbon monoxide reductions: within-subject effects of pay amount. J Appl Behav Anal 17:477-483.
216. Stitzer ML, Bigelow GE, Liebson IA (1982). Comparison of three outpatient methadone detoxification procedures. NIDA Res Monograph 41:239-245.
217. Stitzer ML, McCaul ME, Bigelow GE, Liebson IA (1983). Oral methadone self-administration: effects of dose and alternative reinforcers. Clin Pharmacol Ther 34:29-35.
218. Stitzer ML, Iguchi MY, Felch LI (1992). Contingent take-home incentives: effects on drug use of methadone maintenance patients. J Consult Clin Psychol 60:927-934.
219. Stolerman IP, Goldfarb T, Fink R, Jarvik ME (1973). Influencing cigarette smoking with nicotine antagonists. Psychopharmacologia 28:247-259.
220. Stoops WW, Lile JA, Fillmore MT, Glaser PEA, Rush CR (2005). Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration. Psychopharmacology 182:186-193.
221. Stoops WW, Lile JA, Robbins CG, Martin CA, Rush CR, Kelly TH (2007). The reinforcing, subject-rated, performance, and cardiovascular effects of d-ampheta-mine: influence of sensation-seeking status. Addict Behav 32:1177-1188.
222. Strain EC, Stitzer ML, Liebson IA, Bigelow GE (1993). Dose response effects of methadone in the treatments of opioid dependence. Ann Intern Med 19:23-27.
223. Strain EC, Bigelow GE, Liebson IA, Stitzer ML (1999). Moderate vs. high dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 281:1000-1005.
224. Strain EC, Moody DE, Stoller KB, Walsh SL, Bigelow GE (2004). Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 74:37-43.
225. Strona FV, McCright J, Hjord H, Ahrens K, Tierney S, Shoptaw S, et al. (2006). The acceptability and feasibility of the positive reinforcement opportunity project: a community-based contingency management methamphetamine treatment program for gay and bisexual men in San Francisco. J Psychoactive Drugs Suppl 3:377-383.
226. Sullivan MA, Vosburg SK, Comer SD (2006). Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychophar-macology 189:37-46.
227. Tancer M, Johanson CE (2003). Reinforcing, subjective and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72:33-44.
228. Tancer M, Johanson CE (2007). The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 189:565-573.
229. Tarter R, Vanyukov M, Giancola P, Dawes M, Blackson T, Mezzich A, et al. (1999). Etiology of early age onset substance use disorder: a maturational perspective. Dev Psychopathol 11:657-683.
230. Terner JM, de Wit H (2006). Menstrual cycle phase and responses to drugs of abuse. Drug Alcohol Depend 84:1-13.
231. Thompson T, Schuster CR (1964). Morphine self-administration, food-reinforced and avoidance behaviors in rhesus monkeys. Psychopharmacology 5:87.
232. Veenstra-Vander Weele J, Qaadir A, Palmer AA, Cook EH, de Wit H (2006). Assoication between the Casein Kinase 1 Epsilon gene region and subjective response to D-amphetamine. Neuropsychopharmacology 31:1056-1063.
233. Volkow ND, Fowler JS (2000). Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 10:318-325.
234. Volkow ND, Fowler JS, Wang GJ (2004). The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neurophar-macology 47 (Suppl 1):3.
235. Vuchinich R, Simpson C (1998). Hyperbolic temporal discounting in social drinkers and problem drinkers. Exp Clin Psychopharmacol 6:292-305.
236. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, et al. (2002). The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26:106-114.
237. Weeks JR (1962). Experimental morphine addiction: method for automatic intravenous injections in unrestrained rats. Science 138:143-144.
238. Wikler A (1952). A psychodynamic study of a patient during experimental self-regulated re-addiction to morphine. Psychiatr Q 26:270-293.
239. White T, Justice AJH, de Wit H (2002). Differential subjective effects of d-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 73:729-741.
240. Yoon JH, Higgins ST, Heil SH, Sugarbaker RJ, Thomas CS, Badger GJ (2007). Delay discounting predicts postpartum relapse to cigarette smoking among pregnant women. Exp Clin Psychopharmacol 15:176.
241. Zacny JP, McKay MA, Toledano AY, Marks S, Young CJ, Klock PA, et al. (1996). The effects of a cold water immersion stressor on the reinforcing and subjective effects of fentanyl in healthy volunteers. Drug Alcohol Depend 42:133-142.